期刊文献+

比较三阴性和非三阴性乳腺癌临床特征及术后不同时间局部复发率、远处转移率 被引量:2

下载PDF
导出
摘要 目的:探究三阴性和非三阴性乳腺癌临床特征及术后不同时间局部复发率、远处转移率差异。方法:选择1168例原发性乳腺癌并行根治术治疗的女性患者,对比三阴性和非三阴性乳腺癌患者的临床特征,并采取随访的方式就其术后不同时间局部复发率、远处转移率进行分析。结果:相比于非三阴性乳腺癌患者,三阴性乳腺癌患者年龄偏小、肿瘤体积偏大、浸润性导管癌占比较高(P<0.05);三阴性乳腺癌患者术后3年及5年生存率低于非三阴性乳腺癌患者(P<0.05),复发率和远处转移率高于非三阴性患者(P<0.05);结论:三阴性乳腺癌患者具有其独特的临床特征,特点为发病年龄小、瘤体体积偏大,且术后局部复发、远处转移率较高,术后生存时间相对较短。
作者 杨乐艺
出处 《包头医学院学报》 CAS 2019年第7期44-45,共2页 Journal of Baotou Medical College
  • 相关文献

参考文献5

二级参考文献42

  • 1孙燕 周际昌.临床肿瘤内科手册[M].北京:人民卫生出版社,1998.45.
  • 2Eisenhauer EA,Therasse P,Bogaerts J,et al.New response evalua- tion criteria in solid tumours:revised RECIST guideline(version 1.1)[J].Eur J Cancer,2009,45(2):228-247.
  • 3Gunduz N,Fisher B,Saffer EA.Effect of surgical removal on the growth and kinetics of residual tumor[J],Cancer Res,1979,39(10):3861-3865.
  • 4Fisher B,Gunduz N,Coyle J,et al.Presence of a growth-stimulat- ing factor in semen following prinutry tumor removal in mice[J]. Cancer Res,1989,49(8):1996-2001.
  • 5Fisher B,Gunduz N,Saffer EA.Influence of the interval between primary tumor removal and chemotherapy on kinetics and growth of metastases[J].Cancer Res,1983,43(4):1488-1492.
  • 6Brock N.Results of surgery and cyclophosphamide on rat shay chloroleukemia[J].Strahlentherapie,1959,41:347-354.
  • 7Carey LA,Dees EC,Sawyer L,et al.The triple negative paradox: primary tumor chemosensitivity of breast cancer subtypes[J].Clin Cancer Res,2007,13(8):2329-2334.
  • 8Iwata H,Sato N,Masuda N,et al,Docetaxel followed by fluo- rouracil/epirubicin/cyclophosphamide as neoadjuvant chemotherapy for patients with primary breast cancer[J].Jpn J Clin Oncol,2011,41(7):867-875.
  • 9Warm M,Kates R,Grosse-Onnebrink E,et al.Impact of tumor bi- ology,particularly triple-negative status,on response to pre-oper- ative sequential,dose-dense epirubicin,cyclophosphamide fol- lowed by docetaxel in breast cancer[J].Anticancer Res,2010,30?10):4251-4259.
  • 10Torrisi R,Balduzzi A,Ghisini R,et al.Tailored preoperative treatment of locally advanced triple negative(hormone receptor negative and HER2 negative)breast cancer with epirubicin,cis- platin,and infusional fluorouracil followed by weekly paclitaxel [J].Cancer Chemother Pharmacol,2008,62(4):667-672.

共引文献89

同被引文献28

引证文献2

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部